Hematology Clinical Trial Expertise

Developing cures and treatments for blood diseases, genetic blood disorders, and blood cancers is complicated

Millions of people are affected by blood disorders each year.   While treatments continue to advance, the field of hematology grows increasingly complicated.  Whether the blood disease is genetic or acquired, whether it has invaded the blood cells, platelets, bone marrow, vascular endothelium, or plasma proteins, our team of scientific-minded experts are equipped to help bring your hematology therapies to market.

Veristat has supported more than 250 projects and marketing applications for blood diseases, genetic disorders, and cancers. 

Overcoming Clinical Trial Challenges for Blood Disorders

Veristat has guided clients through the conduct of more than 250 projects and over 30 marketing applications for blood diseases. Our experience spans clinical development consulting, full clinical trial oversight, and regulatory submission preparation for rare genetic blood disorders and autoimmune blood diseases, as well as blood cancers.

At Veristat, our experienced teams are poised to plan and implement these efforts quickly providing:     


Our Malignant & Non-Malignant Blood Disease Expertise

Experience in Malignant Blood Disorders
   Acute Myeloid Leukemia (AML)    Mantle Cell NHL
   B-Cell Lymphoma    Multiple Myeloma (MM)
   Blastic Plasmacytoid Dendritic Cell Neoplasm    Myelodysplastic Syndrome (MDS)
   Chronic Lymphocytic Leukemia (CLL)    Myeloid Leukemia
   Cutaneous T-Cell Lymphoma    Peripheral T-cell Lymphoma (PTCL)
   Diffuse Large B-Cell Lymphoma (DLBCL)    Systemic Mastocytosis (SM)
   Follicular Lymphoma    T Cell Lymphoma
   Hodgkin’s Lymphoma and Non-Hodgkin's Lymphoma    Waldenstrom's Macroglobulinemia
   Mantle Cell Lymphoma   


Experience in Non-Malignant Blood Disorders
   Automated Blood Testing Device    Hemophilia
   beta-Thalassemia    Hereditary Angioedema (HAE)
   Blood Coagulation Testing    Idiopathic Thrombocytopenic Purpura
   Blood Transfusions, Transfusion-induced Iron Overload    Primary Hemophagocytic Lymphohistiocytosis
   Bone Marrow Transplant    Pyruvate kinase deficiency
   Cold Agglutinin Disease (CAD)    Sickle Cell Disease
   Essential Thrombocythemia; Myelofibrosis; Polycythemia vera    Thalassemia
   Hemophagocytic Lymphohistiocytosis (HLH)    Thrombocythemia Myelofibrosis
   Hemorrhage and Hemostasis    Wiskott-Aldrich Syndrome (WAS)


FDA Approval - The True Proof of Success

Veristat supports the first targeted therapy for adult patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 mutation.

success-quotes"I have personally had the priviledge to work with a dedicated Agios team on the IND application, phase I study, and NDA submission for ivosidenib. I am thrilled to see TIBSOVO® receive FDA approval and look forward to seeing this therapy help improve the lives of patients with R/R AML."

Barbara Balser, VMD, Veristat Executive VP & Chief Scientific Officer

Learn More with These Resources

Fact Sheet

Hematology Fact Sheet

Veristat's hematology experience spans clinical development consulting, full clinical trial oversight, and regulatory submission preparation for rare genetic blood disorders ...


Case Study

Running Successful Clinical Programs with an External ...

A biopharmaceutical firm specializing in rare and ultra-rare disease research started working with Veristat over 7 years ago.


Request A Proposal